Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional ...

Building on clinical data from millions of individuals who received lipid-encapsulated mRNA vaccines, the FDA has issued new guidance that could facilitate a faster transition to first-in-human trials ...

Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on real-world evidence ...

Adoption of Triple Combination Therapy Accelerates at Unprecedented Rates as Precision Medicine Revolution ContinuesRockville, MD, Jan. 29, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Evotec, Yonsei University, and Zymedi have been awarded a US$ 4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop fir ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is the most common cause of chronic liver disease in children. MASLD ...